$SYK

General Dynamics Land Systems received a $135.9M contract modification from the U.S. Army to upgrade Stryker armored vehicles' power systems, increasing the total contract value to $162.4M. The contract, running until 2030, covers retrofit kits for existing Strykers, though specifics on quantities and timelines were not disclosed. General Dynamics was the sole bidder. This follows another $54.3M contract for Stryker maintenance and sustainment through 2031.

Stryker (NYSE:SYK) completed its acquisition of privately held ZuriMED, adding the FiberLocker System to its Sports Medicine portfolio. The FiberLocker System is a rotator cuff augmentation technology designed to enhance repair strength. The acquisition expands Stryker's shoulder care capabilities, according to the company.

Stryker Ireland Ltd faces charges for alleged health and safety breaches following the death of a contractor's employee at its Cork plant. The incident occurred in 2023, and the company is accused of failing to manage risks that led to fatal injuries. Stryker is scheduled to appear in court again in December. According to the Health and Safety Authority, the company failed to prevent titanium particles from entering the HVAC system, exposing workers to risks.

Diamond Hill Capital's Q3 2026 investor letter highlights Stryker Corp. (SYK) as a new portfolio addition, citing its broad product portfolio, innovation, and market share growth potential. SYK closed at $294.66 on October 16, 2026, with a market cap of $113.02B and TTM revenue of $25.84B, after a 16.16% YTD pullback.

Stryker (SYK) invested $400M in CMR Surgical, gaining exclusive U.S. sales rights for its Versius robotic surgery system. The deal includes an option to acquire CMR fully. Stryker aims to expand into soft-tissue robotics, complementing its Mako platform. CMR will focus on global sales outside the U.S. while Stryker leads U.S. commercialization.

Stryker Corporation has appointed Spencer Stiles as its next CEO, effective January 1, 2027. Current CEO Kevin Lobo will become executive chair. The company also announced a $400 million investment in CMR Surgical to support its Versius surgical robotics portfolio. Stryker reported Q2 2026 revenue of $6.59 billion, a 9.40% increase year-over-year, with adjusted earnings per share of $3.69, exceeding estimates.

Stryker's CEO Kevin Lobo will step down, with COO Spencer Stiles taking over on 1 January 2027. Viatris plans to acquire Pacira BioSciences for US$1.65bn. Johnson & Johnson raised its full-year revenue guidance to US$101.2bn after Q3 earnings beat estimates. Google partnered with Flo Health to integrate the Flo app into Google Fitbit.

Stryker invested $400M in CMR Surgical, securing US distribution rights and an acquisition option. Undecimal Bio raised €16M for RNA medicine platform. Stride secured £4.6M for preventative health testing. MHRA launched 2030 Healthcare Innovation Strategy. EU allocated €80M for Health-AI compute. AstraZeneca partnered with insitro for $1.5B AI target discovery. Siemens Healthineers exited general ultrasound. Philips updated Lumify ultrasound guidance.

Neogen (NEOG) reported Q2 revenue of $222.8M, up 6.5% YoY, beating estimates. CooperCompanies (COO) reported flat revenue, missing expectations. Abbott (ABT) reported $12.59B revenue, up 13% YoY, beating estimates. Stryker (SYK) reported $6.59B revenue, up 9.4% YoY, meeting expectations. Stocks reacted accordingly to the results.

Stryker received FDA 510(k) clearance for its Sonopet 3 device, designed with input from surgeons to enhance power, precision, and versatility in tissue removal. The platform includes advanced technologies like RISE and Pulse Control, aiming to streamline surgical workflows. Clinical use is expected to begin in October, with a full commercial launch later this fall, according to the company.